Abstract:The human γ-aminobutyric acid (GABA) transporter 1 (hGAT-1) is the first member of the solute carrier 6 (SLC6) protein superfamily. GAT-1 ( SLC6A1 ) is one of the main GABA transporters in the central nervous system. Its principal physiological role is retrieving GABA from the synapse into neurons and astrocytes, thus swiftly terminating neurotransmission. GABA is a key inhibitory neurotransmitter and shifts in GABAergic signaling can lead to pathological conditions, from anxiety and epileptic seizures to schizophrenia. Point mutations in the SLC6A1 gene frequently give rise to epilepsy, intellectual disability or autism spectrum disorders in the afflicted individuals. The mechanistic routes underlying these are still fairly unclear. Some loss-of-function variants impair the folding and intracellular trafficking of the protein (thus retaining the transporter in the endoplasmic reticulum compartment), whereas others, despite managing to reach their bona fide site of action at the cell surface, nonetheless abolish GABA transport activity (plausibly owing to structural/conformational defects). Whatever the molecular culprit(s), the physiological aftermath transpires into the absence of functional transporters, which in turn perturbs GABAergic actions. Dozens of mutations in the kin SLC6 family members are known to exhort protein misfolding. Such events typically elicit severe ailments in people, e.g., infantile parkinsonism-dystonia or X-linked intellectual disability, in the case of dopamine and creatine transporters, respectively. Flaws in protein folding can be rectified by small molecules known as pharmacological and/or chemical chaperones. The search for such apt remedies calls for a systematic investigation and categorization of the numerous disease-linked variants, by biochemical and pharmacological means in vitro (in cell lines and primary neuronal cultures) and in vivo (in animal models). We here give special emphasis to the utilization of the fruit fly Drosophila melanogaster as a versatile model in GAT-1-related studies. Jointly, these approaches can portray indispensable insights into the molecular factors underlying epilepsy, and ultimately pave the way for contriving efficacious therapeutic options for patients harboring pathogenic mutations in hGAT-1.

Structure, function, and plasticity of GABA transporters

Plasticity of GABA transporters: an unconventional route to shape inhibitory synaptic transmission

Functional and Pharmacological Aspects of GABA Transporters

Translational Patterns of Ionotropic Glutamate and GABA Receptors During Brain Development and Behavioral Stimuli Revealed by Polysome Profiling

GABA Metabolism and Transport: Effects on Synaptic Efficacy

Ways of modulating GABA transporters to treat neurological disease

Regulation Of Glutamate Transporter Function

Gaba Transporter-1 Activity Modulates Hippocampal Theta Oscillation And Theta Burst Stimulation-Induced Long-Term Potentiation

GABA(A) receptor diversity and pharmacology

The Role of N‐glycosylation in the Stability, Trafficking and GABA‐uptake of GABA‐transporter 1

The role of N-glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal N-glycans facilitate efficient GABA-uptake activity of the GABA transporter.

Molecular basis for substrate recognition and transport of human GABA transporter GAT1

A Reappraisal of GAT-1 Localization in Neocortex

Cation-chloride cotransporters in neuronal development, plasticity and disease

Molecular and Clinical Repercussions of GABA Transporter 1 Variants Gone Amiss: Links to Epilepsy and Developmental Spectrum Disorders

Electrophysiology of ionotropic GABA receptors

Transport mechanism and pharmacology of the human GlyT1

[High-Affinity Glutamate Transporters].

Localization and expression of GABA transporters in the suprachiasmatic nucleus

Evolution of Neurotransmitter Gamma-Aminobutyric Acid, Glutamate and Their Receptors

Transportation and Role of GABAA Receptor in Neurological Diseases